Ceryvyn Therapeutics Limited
CKDXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.64M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.64 Million |
|---|---|
| Enterprise Value | $-7,495,640.00 |
| Earnings per Share | $0.16 |
| Beta | 1.51 |
| Outstanding Shares | 1,367,978,173 |
Return
| Return on Equity | 236.09% |
|---|---|
| Return on Assets | 223.99% |
| Return on Invested Capital | -1456.51% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 46903.45 |
| Enterprise Value to EBIT | -12.86 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 23, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$348,375
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Opthea Limited
33 employees
CEO: Megan Baldwin
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D...